The p38 mitogen-activated protein kinase (MAPK) pathway plays a critical role in skeletal muscle differentiation. However, the relative contribution of the four p38 MAPKs (p38a, p38b, p38c and p38d) to this process is unknown. Here we show that myoblasts lacking p38a, but not those lacking p38b or p38d, are unable to differentiate and form multinucleated myotubes, whereas p38c-deficient myoblasts exhibit an attenuated fusion capacity. The defective myogenesis in the absence of p38a is caused by delayed cell-cycle exit and continuous proliferation in differentiation-promoting conditions. Indeed, activation of JNK/cJun was enhanced in p38a-deficient myoblasts leading to increased cyclin D1 transcription, whereas inhibition of JNK activity rescued the proliferation phenotype. Thus, p38a controls myogenesis by antagonizing the activation of the JNK proliferation-promoting pathway, before its direct effect on muscle differentiation-specific gene transcription. More importantly, in agreement with the defective myogenesis of cultured p38a D/D myoblasts, neonatal muscle deficient in p38a shows cellular hyperproliferation and delayed maturation. This study provides novel evidence of a fundamental role of p38a in muscle formation in vitro and in vivo.
Introduction
Regulation of skeletal muscle formation (myogenesis) is essential for normal development as well as in pathological conditions such as muscular dystrophies and inflammatory myopathies in which prominent muscle loss and regeneration take place. Myogenesis is a dynamic process in which mononucleated undifferentiated myoblasts first proliferate, then withdraw from the cell cycle, and finally differentiate and fuse to form the multinucleated mature muscle fibers in the animal. This process is controlled by the MyoD family of muscle-specific basic helix-loop-helix proteins, known as muscle regulatory factors (MRFs), which in concert with members of the ubiquitous E2A and myocyte enhancer factor-2 (MEF2) families, activate the differentiation program by inducing transcription of regulatory and structural musclespecific genes (Sartorelli and Caretti, 2005; Tapscott, 2005) . The association of the myogenic effector transcription factors to E boxes on muscle loci and also their transcriptional activities are controlled by intracellular signaling pathways in response to yet to be identified extracellular cues. A signaling pathway that plays a fundamental role in myogenesis involves p38 mitogen-activated protein kinase (MAPK) (Keren et al, 2006; Lluis et al, 2006) . p38 kinase activity increases over the course of differentiation and is required for full myoblast differentiation and fusion. In mammals, there are four p38 MAPKs, p38a, p38b, p38g and p38d, which are phosphorylated and activated by MAPK kinases MKK6/3 . Once activated, p38 MAPKs phosphorylate serine/threonine residues of their substrates, which include transcription factors as well as protein kinases. Functional analysis of p38a and p38b MAPKs in different cellular processes, including myogenesis, has been facilitated by the availability of pyridinyl imidazole compounds, such as SB203580, which inhibit both p38 isoforms. Indeed, treatment with SB203580 prevents the fusion of immortalized myoblasts into myotubes as well as the induction of muscle-specific genes, demonstrating the requirement of p38a/b in myogenesis (Cuenda and Cohen, 1999; Zetser et al, 1999; Li et al, 2000; Wu et al, 2000) . The specific mechanisms by which p38a/b impinges upon the muscle regulatory pathway have been described in recent papers. p38a/b augments the transcriptional activity of MEF2A and MEF2C by direct phosphorylation, promotes MyoD/E-protein heterodimerization and targets chromatin-remodeling enzymes to musclespecific loci (Zetser et al, 1999; Zhao et al, 1999; Wu et al, 2000; Simone et al, 2004; Lluis et al, 2005) , thereby inducing transcription of muscle-specific genes. p38a/b can also increase the stability of critical muscle-specific transcripts (Briata et al, 2005) . Recent in vivo studies with SB203580 have further demonstrated that p38 signaling is a crucial determinant of myogenic differentiation during early embryonic myotome development in mouse and Xenopus (de Angelis et al, 2005; Keren et al, 2005) . Because of the lack of p38g and p38d pharmacological inhibitors, the involvement of these kinases in myogenesis remains unclear.
Taken together, the p38 signaling pathway appears to control myoblast differentiation both in vitro and in embryonic models; however, the specific impact and relative contribution of the individual p38 family members to myogenesis remains unsolved. We have addressed this question through a genetic approach, by using primary myoblasts derived from skeletal muscle of neonatal mice deficient in p38a, p38b, p38g and p38d, as well as by analyzing the phenotype of neonatal muscle. Our findings have allowed us to characterize for the first time the specific role of each p38 MAPK in skeletal myogenesis. From these studies, p38a emerges as the critical p38 MAPK in this process.
Results

Expression pattern of p38 MAPKs in primary myoblasts
Myoblasts proliferate in culture as undifferentiated cells in growth medium (GM) characterized by high serum content; upon confluence and serum withdrawal (differentiation medium, DM), myoblasts differentiate into myocytes, which subsequently begin to fuse into multinucleated myotubes. We first aimed to analyze the expression and activity of p38 MAPKs in primary myoblasts. p38a, p38b, p38g and p38d transcripts and corresponding proteins were expressed both in GM and DM, as demonstrated by reverse transcriptionpolymerase chain reaction (RT-PCR) and Western blotting analyses, respectively ( Figure 1A and B) (antibody specificity is shown in Supplementary Figure 1 ). p38a and p38g were the most abundant isoforms, p38g being upregulated during differentiation. C2C12-immortalized myoblastic cells were found to express p38a, p38b and p38g, but not p38d, mRNA ( Figure 1A ). Thus, primary myoblasts constitute a more complete myogenic model than C2C12 cells for studying the relative contribution of p38 kinases to myogenesis. p38 phosphorylation was low in non-confluent primary myoblasts in GM, being induced in nearly confluent cells in GM (this time point is referred to as DM 0 h; i.e., the time of transfer of almost confluent myoblasts from GM to DM), and continued to be elevated in DM (Figure 1C, top) . As the single band detected by the anti-phospho-p38-antibody could represent the activated form of all four p38 kinases, analysis of isoform-specific p38 activities became pertinent. p38a and p38g kinase activities were induced in differentiating compared to proliferating non-confluent myoblasts ( Figure 1D ). However, we could not determine the activity of the p38b and p38d isoforms due to the inability of the corresponding antibodies to work in immunoprecipitation assays. At variance with the results in primary myoblasts, p38 phosphorylation in C2C12 cells was detected only after 12 h in DM ( Figure 1C, bottom) , indicating an advancement in the kinetics of p38 activation in primary myoblasts. Similarly, the expression of myogenin (a marker of early differentiation) was advanced in primary myoblasts compared to C2C12 cells ( Figure 1E ; compare DM 0 and 12 h), suggesting a correlation between the early activation of p38 and the precocious induction of muscle differentiation-specific genes in primary cells in high serum proliferating conditions. In agreement with this, the expression of late differentiation markers (muscle creatine kinase (MCK) and MRF4) was also advanced in primary versus C2C12 differentiating myocytes ( Figure 1E ).
Consequences of absence of p38 MAPKs in myoblast differentiation
To directly evaluate the contribution of p38 MAPKs (p38s) to muscle differentiation, we analyzed comparatively the expression of muscle differentiation gene products in p38s-deficient myoblast cultures (p38a
) and corresponding wild-type (WT) cells by quantitative RT-PCR (qRT-PCR), at different intervals in GM and DM. Absence of expression of each p38 isoform in the corresponding p38-deficient myoblasts was confirmed previously (Supplementary Figure 1B) . A similar temporal expression pattern of differentiation markers was observed in WT myoblasts as in those deficient in p38b, p38g and p38d (Supplementary Figure 2A) . By contrast, delayed kinetics and reduced expression of myogenin, MCK and myosin heavy chain (MHC-2X) were exhibited by p38a-deficient myogenic cells ( Figure 2A) . Notably, the deficient myogenic differentiation of p38a D/D myoblasts was rescued by retroviral delivery of p38a (Supplementary Figure 3A) . These results support the conclusion that early and late muscle-specific gene expression is mediated not by all p38 MAPKs, but exclusively by p38a.
Recruitment of the transcriptional machinery to muscle loci is reduced in p38a-deficient myoblasts
Recent reports have shown that the activity and engagement of MyoD/E47 and MEF2 transcription factors and chromatinassociated enzymes such as Brg1 and RNA polymerase II (Pol II) on muscle promoters can be regulated by SB203580 treatment and/or MKK6 overexpression in myogenic cell lines (Penn et al, 2004; Simone et al, 2004; Lluis et al, 2005) . On the basis of the results shown so far in this study, we hypothesized that the p38a isoform would mediate the recruitment of these chromatin-associated activities to muscle genes in primary myoblasts. Chromatin immunoprecipitation (ChIP) assays demonstrated that MyoD and MEF2 were specifically associated with the promoter regions of myogenin and MCK genes in WT cells ( Figure 2B ). Of note, binding of these myogenic transcription factors to the myogenin promoter was detected already in GM (DM 0 h) ( Figure 2B , left), in agreement with the precocious expression of myogenin transcripts in primary myoblasts in high serumrich medium ( Figures 1E and 2A) . However, the recruitment of these factors to the myogenin and MCK gene promoters was compromised in p38a D/D myoblasts. Furthermore, deficiency in p38a also prevented the engagement of RNA Pol II on both muscle loci ( Figure 2B ). To directly demonstrate functional consequences of p38a deficiency on musclespecific transcription, promoter-reporter analyses using Myogenin-Luc, MCK-Luc and p4RE-tk-Luc (containing four multimerized E boxes) plasmids were performed. Luciferase activities from all three promoters were lower in p38a
myoblasts than in WT cells ( Figure 2C ); more importantly, these activities could be rescued by ectopic delivery of p38a, confirming that the absence of p38a is responsible for the transcriptional defect. These results extended to primary myoblasts the previously reported effect of pharmacological inhibition of p38a/b on early and late muscle-specific gene transcription in myoblast cell lines, and demonstrated the 
Consequences of absence of p38 MAPKs in myoblast fusion
To directly investigate the contribution of p38 MAPKs to myoblast fusion, we examined the capacity of WT and p38-deficient myoblasts to form plurinucleated myotubes in DM. Differentiated WT myoblasts displayed a multinucleated morphology, which was similarly observed in cells deficient in p38b, p38g and p38d, whereas p38a-deficient myocytes were primarily uninuclear, exhibiting a severe defect in their ability to form multinucleated cells, even after 48 h DM ( Figure 3A ; Supplementary Figure 4) . Notably, this defect could be rescued by retroviral delivery of p38a (Supplementary Figure 3B) . Fusion was also impaired in SB203580-treated WT myoblasts in DM (not shown).
Although myotube formation did occur in p38g-deficient myoblasts, it was attenuated with respect to WT cells, as evidenced by the reduced fusion index and total number of myotubes formed ( Figure 3B ). From these results, we speculated that potential redundancies and/or compensatory mechanisms might be occurring among the isoforms. Accordingly, we showed that the expression pattern of phosphorylated p38 during myogenesis was indistinguishable between WT myoblasts and myoblasts deficient in p38b, p38g and p38d ( Figure 3C ); indeed, no significant changes in the expression of the different p38 isoforms were observed in myoblasts deficient in p38b, p38g and p38d (not shown), in contrast, the levels of phosphorylated p38 were markedly reduced in p38a D/D myoblasts, which could be attributed to the diminished expression of p38b and p38g in these cells (Supplementary Figure 1C) .
Delayed cell-cycle exit correlates with impaired differentiation of p38a-deficient myoblasts
The simultaneous expression of myogenin and activation of p38 in nearly confluent primary myoblasts in GM (Figure 1C -E; DM 0 h), together with the reported implication of p38 in the proliferation of several cell types (Haq et al, 2002; Lee et al, 2002; Engel et al, 2005; Faust et al, 2005) , suggested that the differentiation defect of p38a-deficient myoblasts could be caused, at least in part, by alterations in cell-cycle exit. To test this hypothesis, we analyzed potential differences in the percentage of cells in S phase among the different p38- and WT cells by determining the incorporation of bromodeoxyuridine (BrdU) at different intervals after transfer to low-serum DM. As shown in Figure 4A , after 12 h in DM, 45% of p38a-deficient myoblasts remained in S phase compared with 30% of WT; differences in S-phase myoblasts were still observed after 24 and 36 h in DM, with 32% and 18% BrdU-positive p38a-deficient cells versus 10% and 3% BrdUpositive WT cells, respectively. In contrast, no significant alterations were observed in myoblasts deficient in p38b, p38g or p38d kinases ( Figure 4B) . Notably, the proliferation phenotype of p38a D/D myoblasts in DM was rescued by retroviral delivery of p38a ( Figure 4A ). Moreover, FACS analysis showed an increased population of p38a-deficient myoblasts in G2/M and S phases of the cell cycle compared with WT myoblasts after 24 h in DM (Supplementary Figure  5A) . Altogether, these experiments evidenced that p38a
) myogenic cells display continued proliferation under conditions of low serum that normally induce cell-cycle withdrawal and terminal differentiation of WT myoblasts, indicating that myoblasts deficient in p38a have an impaired ability to exit the cell cycle. Figure  5C) , suggesting that the delayed and reduced expression of differentiation-specific genes in p38a D/D cells cannot be ascribed to defects in expression of MRFs operating in proliferation and early differentiation stages.
Altered expression of cell-cycle regulators in p38a-deficient myoblasts
To directly investigate the causes of the enhanced proliferation of p38a D/D cells, we searched for potential differences in cell-cycle-associated proteins, whose expression is known to be modulated in myogenesis upon GM to DM transfer (Kitzmann and Fernandez, 2001 ). qRT-PCR and immunoblotting analyses showed that cyclin D1 mRNA and protein expression, respectively, decreased rapidly in WT myoblasts after transfer to DM, whereas they were still readily detected in p38a-deficient myoblasts after 48 h in DM ( Figure 5A and B). Potential regulation by p38a deficiency of cyclin E was observed both at the mRNA and protein levels ( Figure 5A and B), but was less dramatic, and may therefore be due to secondary effects of changes in cyclin D1. Indeed, cyclin D1 is known to be essential for the induction of cyclin E in other cell types (Nurse, 1994; Sherr, 1994) . The lack of any significant regulation of cyclin B1 and p21 in p38a D/D myoblasts also indicated that the effects of p38a deficiency on cyclin D1 were specific. The pRb protein dephosphorylation is required for full cell-cycle exit and initiation of the myogenic program (Halevy et al, 1995) . Importantly, myoblasts lacking p38a contained a substantially higher level of hyperphosphorylated pRb than did WT control cells in DM, which was also maintained for longer periods of time, indicating than pRb dephosphorylation was delayed and defective in p38a
myoblasts ( Figure 5C ). If p38a contributes causally to downregulation of cyclin D1 levels and subsequent activation of myogenic differentiation, then its constitutive activation should be sufficient for advancing or even inducing both events in proliferation-promoting conditions. Indeed, C2C12 cells stably expressing a constitutively active form of MKK6-presenting high levels of activated p38 ( Figure 5D )-exhibited a pronounced reduction of cyclin D1 levels and phosphorylated pRb coincident with induction of myogenin Figure 5D ). Together, these results suggest that p38a activity is required to downregulate cyclin D1 expression and pRb hyperphosphorylation, leading to an irreversible block in G1-to-S progression and commencement of myogenic differentiation.
Persistent activation of JNK/cJun underlies the continuous proliferation of p38a-deficient myoblasts Antagonistic effects of p38 and JNK signaling pathways in myoblast differentiation have been described (Meriane et al, 2000) . However, the implication of JNK in this process is controversial (Meriane et al, 2000; Khurana and Dey, 2004) . Within this context, we analyzed the activation of JNK in WT and p38a-deficient myoblasts. JNK phosphorylation was high in WT myoblasts in GM, dropping as cells reached confluency (DM 0 h), and remained low after transfer to DM; in contrast, JNK activity continued to be elevated in p38a-deficient myoblasts in DM, and, notably, it could be reduced by retroviral delivery of p38a (Supplementary Figure 6A) . This persistent JNK activity was translated into the phosphoryla- Figure 6 Increased JNK activity contributes to the enhanced proliferation of p38a-deficient myoblasts. WT and p38a D/D myoblasts were cultured as in Figure 5 . (A) Phosphorylated JNK and Ser63-phosphorylated cJun were analyzed by Western blotting using anti-phosphospecific antibodies. Numbers show quantification of phospho-proteins normalized to total JNK and cJun levels. (B) qPCR analysis of the relative cJun mRNA levels (top). ChIP analysis was performed using an anti-cJun antibody, and PCR was performed with primers corresponding to the cyclin D1 promoter region (bottom). (C) p38a D/D primary myoblasts were cultured in DM for the indicated hours, in the absence or presence of D-JNKI1 and SP600125 (JNK inhibitors), and incubated for 1 h with BrdU. BrdU-positive cells were quantified as in Figure 4 . The effect of D-JNKI1 and SP600125 on JNK activation is shown in Supplementary Figure 6B . (D) Cells were cultured as in (C), and mRNA for the indicated myogenic markers was analyzed by qPCR. (E) p38a activity is necessary for myogenic differentiation, independent of cell-cycle withdrawal. Myoblasts cultured in GM were shifted to DM for 24 h and then cultured for an additional 24 h period in DM alone or DM supplemented with SB203580. mRNA for the indicated myogenic markers was analyzed by qPCR. (F) Reduced MKP-1 levels in p38a-deficient myoblasts. Myoblast extracts used in (A) were analyzed by Western blotting using anti-MKP-1 and anti-tubulin antibodies. tion of its downstream substrate cJun on Ser63 ( Figure 6A ). Furthermore, cJun mRNA levels were also increased in p38a D/D myoblasts ( Figure 6B ), suggesting that p38 regulates cJun gene expression indirectly, possibly via JNK/AP-1-mediated transcription from the cJun promoter (Angel et al, 1988) . Of note, ChIP experiments revealed an increased association of cJun to the cyclin D1 promoter in p38a-deficient myoblasts in DM ( Figure 6B ), supporting the notion of a cJun-mediated transcriptional induction of the cyclin D1 gene in these cells. These results suggested the existence of crosstalk between JNK and p38 signaling pathways in myogenesis, which might underlie the proliferation phenotype of myoblasts lacking p38a. To obtain evidence that persistent activation of JNK could be responsible for the continuous proliferation of p38a-deficient myoblasts in differentiation-promoting conditions, BrdU incorporation in these cells was determined in DM in the absence or presence of the specific JNK inhibitor, D-JNKI1 (Borsello et al, 2003) (Supplementary Figure 6B) . As shown in Figure 6C , the number of BrdU-positive p38a-deficient myoblasts was reduced by D-JNKI1 treatment to the levels obtained with WT myoblasts. Similar inhibitory effects on myoblast proliferation were also observed with another JNK inhibitor (SP600125) ( Figure 6C ; Supplementary Figure 6B ), thereby demonstrating that inhibition of JNK activation reduced the proliferation of p38a-deficient myoblasts in differentiating conditions. Taken together, our results indicate that p38a controls myoblast proliferation by downregulating JNK pathway activation. On the basis of an early study by Bennett and Tonks, showing that overexpression of the MAPK phosphatase-1 (MKP-1) in C2C12 cells modulated myogenesis (Bennett and Tonks, 1997) , we hypothesized that the enhanced activation of JNK in p38a-deficient proliferating myoblasts might involve deregulation of this phosphatase. As shown in Figure 6F , the expression of MKP-1 was, indeed, reduced in p38a D/D compared to WT myoblasts in DM, and this reduction could be significantly reversed by retroviral delivery of p38a (Supplementary Figure 6C) , suggesting that p38a may regulate MKP-1 expression. These results further suggested that the downregulation of MKP-1 levels could, in turn, be partially responsible for the persistent phosphorylation of JNK in the absence of p38a.
p38a regulates muscle-specific gene expression independently of cell-cycle exit
The continuous myoblast proliferation in the absence of p38a shown so far may suggest that the impaired muscle-specific gene expression in p38a-deficient myoblasts is secondary to the primary proliferation defect. However, the expression of myogenin and MCK in myoblasts lacking p38a was not rescued by inhibition of JNK activation ( Figure 6D ), suggesting that functional p38a activity is necessary not only for cessation of proliferation but also for commencement of the muscle gene program. To investigate further whether p38a can exert a direct effect on myoblast differentiation, independent of its antiproliferative function, p38a/b activity was inhibited in WT myoblasts after cell-cycle exit and its consequences on muscle gene expression were analyzed subsequently. To this end, WT myoblasts were cultured for 24 h in DM to allow cell-cycle withdrawal, as shown by the absence of phosphorylated pRb (Supplementary Figure 6D) ; then, cells were further incubated for an additional period of 24 h in DM in the absence or presence of SB203580 to evaluate the effect of p38a inhibition exclusively on muscle-specific gene expression. As shown in Figure 6E , the late SB203580 cell treatment resulted in a reduction in the expression of myogenin, MCK and MHC mRNAs compared to myoblasts cultured for 48 h in DM in the absence of the inhibitor. These results, together with those shown in Figure 2B , uncouple two tightly linked functions of p38a in myogenesis, and demonstrate that p38a controls sequential steps in the myogenic pathway.
Mice lacking p38a exhibit increased myoblast proliferation and delayed myofiber growth and maturation in the neonatal period Our previous results in cultured muscle cells indicated that p38a regulated different myogenic stages. To investigate whether p38a could play similar functions in vivo, we analyzed limb muscles from neonatal p38a Figure 7A) , suggesting in vivo compensations of the observed phenotype in vitro. Similarly, no major differences were detected in muscles of p38b D/D and p38d D/D mice, respectively (not shown). To exclude a possible correlation of these observations with the presence of structural abnormalities and muscle damage secondary to the absence of p38a, we labeled apoptotic cells with an antibody against the activated form of caspase-3 and performed transmission electron microscopy studies. No differences were observed between WT and p38a D/D neonatal mice in skeletal muscle apoptotic rates (Supplementary Figure 7B) . Moreover, the ultrastructure of myofibrils and sarcomeres was preserved in p38a D/D neonatal muscle (Figure 8 ). 
Discussion
The p38 MAPK has emerged in the last years as a fundamental pathway in myogenesis. This conclusion has relied largely on studies performed in immortalized myogenic cell lines, by using pyridinyl imidazole inhibitors such as SB203580, which are inhibitors of both p38a and p38b kinases, and by overexpressing constitutively active and kinase-dead forms of components of the signaling pathway. Thus, the relative contribution of the four p38 MAPKs to myogenesis is unknown. In addition, no in vivo studies beyond the embryonic stages have been performed. Here, we demonstrate that p38 kinases play distinct roles in myogenesis, p38a being the crucial kinase. Myoblasts obtained from mice lacking p38a showed delayed cell-cycle exit and continued proliferation, as well as impaired myoblast differentiation and fusion. Moreover, skeletal muscle from neonatal mice deficient in p38a displayed increased myoblast proliferation, reduced myofiber growth and delayed maturation. In contrast, lack of the p38b and p38d had no major phenotypic consequences in any of these models. p38g-deficient myoblasts presented attenuated fusion in vitro although no major alteration was detected on neonatal muscle. In conclusion, p38a emerges as the central p38 MAPK in myogenesis in vitro and in vivo. We demonstrate a key role for p38a in controlling myoblast proliferation, preceding its direct regulation of the muscle-specific gene program, by antagonizing the JNK/cJun pathway, probably via MKP-1. The function and mechanism of action of p38a in the regulation of myoblast proliferation constitute novel and previously unknown activities of the p38 pathway in skeletal myogenesis. Proliferation and differentiation are mutually exclusive processes in myogenesis. Indeed, cessation of proliferation by downregulation of cyclin D1 and dephosphorylation of pRb is required for initiation of muscle-specific gene expression (Rao et al, 1994; Halevy et al, 1995; Skapek et al, 1995; Novitch et al, 1996 Novitch et al, , 1999 Puri et al, 2001; Guo et al, 2003; Huh et al, 2004) . Thus, the impaired differentiation in the absence of p38a could be attributed to continuous myoblast proliferation, due to the persistence of cyclin D1 and hyperphosphorylated pRb in differentiation-promoting conditions, implying a negative regulation of cyclin D1 by p38a. Transcriptional and post-transcriptional downregulation of cyclin D1 by p38 was previously reported in other cell types, although the molecular mechanisms were not fully understood (Lavoie et al, 1996; Casanovas et al, 2000) . We propose that the increased cyclin D1 expression in p38a-deficient myoblasts, which underlies their continued proliferation, may be caused by cJun-mediated transcriptional induction of the cyclin D1 promoter (see below). Two recent reports have shown that p38a inhibition enables proliferation of adult mammalian cardiomyocytes by promoting cytokinesis (Engel et al, 2005) and overrides fibroblast contact inhibition by impaired accumulation of p27 (Faust et al, 2005) . Interestingly, we observed no differences in the accumulation of p27 in differentiating myoblasts regardless of the presence or absence of p38a (data not shown), suggesting the existence of different cell-type-dependent p38a-controlled proliferation mechanisms. At variance with these reports, p38a seemed dispensable for proliferation of B and T lymphocytes (Kim et al, 2005b) . A recent study also implicated p38a/ b MAPKs in satellite cell activation (Jones et al, 2005) ; however, unspecific effects of the high concentration of SB203580 used in this study, by potential inhibition of additional signaling molecules besides p38a/b (Davies et al, 2000) , cannot be excluded. Crosstalk between p38 and JNK signaling pathways has been previously described in different cell types (Nemoto et al, 1998; Zechner et al, 1998; Chen et al, 2000; Porras et al, 2004) , through undefined mechanisms. In the context of skeletal myogenesis, two studies have suggested opposite roles for JNK activity in muscle differentiation (Meriane et al, 2000; Khurana and Dey, 2004) ; however, neither an involvement of JNK in myoblast proliferation nor a crosstalk with the p38 pathway in myogenesis had ever been reported. Our results demonstrated that JNK activity increased and persisted in myoblasts lacking p38a in differentiation-promoting conditions. Most importantly, JNK activation mediated the increased proliferation potential of p38a-deficient myoblasts, as inhibition of JNK activation completely reversed the proliferation phenotype. Our data further showed that the enhanced activation of JNK in p38a-deficient myoblasts translated into increased levels of its substrate phospho-cJun and subsequent induction of cJun/AP-1-mediated cJun gene transcription, which in turn led to increased recruitment of cJun to the cyclin D1 loci in differentiating myoblasts in vivo, presumably via the AP-1 sites on the cyclin D1 promoter (Bakiri et al, 2000) . Thus, p38a controls myoblast proliferation by antagonizing the proliferation-promoting function of JNK, constituting a novel mechanism whereby p38a regulates myogenesis. This antagonism might be mediated, at least in part, by MKP-1, as suggested by the observed downregulated expression of this phosphatase in DM in the absence of p38a, and its rescue by ectopic reconstitution of p38a levels. Notably, regulation of MKP-1 expression and activity by p38a could be direct, based on studies showing that phosphorylation and acetylation of histone H3 on MKP-1 chromatin in response to stress was dependent on SB203580 cell treatment (Li et al, 2001) , and that catalytic activation of MKP-1 depended on its direct association with p38 (Hutter et al, 2000) .
The studies of p38 function in either myogenic cell lines or primary myoblasts are limited to specific stages of myogenesis, and are isolated from the real developmental context. Thus, in vivo analysis in animal models to confirm the role of p38 becomes pertinent. Targeted inactivation of the mouse p38a gene led to a lethal phenotype (Adams et al, 2000; Tamura et al, 2000) ; in one study, the placental defect could be rescued and at a very low frequency the mutant mice survived (Adams et al, 2000) . Using an embryo-specific CRE line, we were able to show that mutant pups survived to term but died shortly thereafter (L Hui, unpublished observations). p38b, p38g and p38d and double p38g/d knockout mice develop normally into adulthood, suggesting redundant functions among the isoforms (Beardmore et al, 2005; Sabio et al, 2005; Kim et al, 2005a) . Recently, two studies reported alternative approaches for studying the role of p38 MAPK pathway in early myogenic development. Using a MEF2 transgenic reporter mouse, de Angelis et al (2005) found that SB203580 treatment blocked MEF2 activity and differentiation in the somites, whereas commitment to the myogenic lineage was not affected, as the expression of the Myf5 locus was not changed by p38a/b inhibition. In addition, Keren et al (2005) showed that interference with the p38 pathway in early developing Xenopus laevis specifically prevented the expression of XMyf5-at variance with the results in mouse embryos-resulting in several defects in muscle development. Interestingly, we found no decrease in Myf5 expression in the absence of functional p38a MAPK in mouse primary myoblasts (see Figure 4E ). Whether the transcriptional control of Myf5 expression by p38 is specific of Xenopus mesoderm deserves further analysis. In our study, we investigated the impact of specific deletion of p38a, p38b, p38g and p38d on neonatal skeletal muscle. Although the ultrastructure of myofibrils and sarcomeres was preserved, we found increased myoblast proliferation, reduced myofiber growth and delayed differentiation in myofibers of neonatal p38a-deficient mice. No major differences were detected in p38g-deficient muscle at the same neonatal stage, in spite of the reduced fusion index observed in vitro; similarly, no major phenotype was observed in muscles of p38b-and p38d-deficient neonatal mice, highlighting the fact that muscle p38a deficiency is the only one that cannot be compensated in vivo.
This study unambiguously demonstrates that p38a is the central p38 MAPK in myogenesis. Our results, together with previous studies, uncover two distinct roles of p38a along the myogenic pathway: as a regulator of myoblast proliferation and a second role in controlling muscle-specific gene expression. These data also provide the first evidence for p38a signaling in postnatal muscle development.
Materials and methods
Reagents
The p38a/b inhibitor SB203580, JNK inhibitor SP600125 and MEK inhibitor PD098059 (Calbiochem) were used at a final concentration of 10, 20 and 50 mM, respectively. The JNK-specific inhibitor D-JNKI1 (Borsello et al, 2003) was synthesized at the IMP, Vienna, and used at a final concentration of 10 mM.
Mice
Mice carrying the floxed p38a, p38b, p38g and p38d alleles (p38a f/f, p38b f/f, p38g f/f, p38d f/f, respectively) were generated by Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, USA). The p38a f/f were described by Engel et al (2005) ; p38b f/f, p38g f/f, p38d f/f will be described elsewhere. p38af/f mice were crossed to More-CRE knock-in mice. Heterozygous mice (More-cre/p38a D/ þ ) were crossed to the p38a f/f to obtain p38a D/D mice. The protamine-CRE transgenic line was used to generate the deleted allele in the germ line of the p38b, p38g and p38d mutant mice. The genetic background of this intercross was C57BL6/J Â 129Sv. Genotyping primers are described in Supplementary data.
Cell culture and isolation of primary myoblasts
The C2C12, C2C12/MKK6E and 293T cell lines were cultured as described in Supplementary data. Primary myoblasts were obtained from muscles of mice deficient in p38a, p38b, p38g, p38d (p38a , respectively) and from their corresponding WT counterparts. Isolation and culture were performed as described in Supplementary data.
Plasmid constructs, transfection and retroviral infection
The following plasmids were used: pEFmlink-p38a, pEFmlinkp38b, pEFmlink-p38g, pEFmlink-p38d, pMyogenin-Luc, pMCK-Luc and p4RE-TK-Luc, and MSCV-p38a retroviral construct. 293T cells and primary myoblasts were transiently transfected by standard methods. Luciferase assay, and details of plasmids, transfection and infection procedures are described in Supplementary data.
Proliferation and fusion assays
To detect S-phase cells, cultures were pulsed with BrdU (Sigma) for 1 h and then were processed and analyzed as described in Supplementary data. For fusion analysis, cells were immunostained with embryonic myosin heavy chain (eMHC) antibody as described in Supplementary data.
RNA isolation, RT-PCR and qRT-PCR
RNA was analyzed by RT-PCR or qRT-PCR. DNA primers and details of the procedure are described in Supplementary data.
Chromatin immunoprecipitation assays
Standard ChIP assays were performed using commercial antibodies against MyoD, MEF2, cJun (Santa Cruz) and RNA Pol II (Abcam). Details of ChIP analysis (including DNA primers and PCR conditions) are described in Supplementary data.
Western blotting, immunoprecipitation and kinase assay
Preparation of cell lysates, Western blotting, immunoprecipitation and in vitro kinase reactions were performed as described in Supplementary data. 
Histology and immunohistochemistry
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
